Enveric Biosciences reported a net loss of $4.0 million for Q4 2025 and provided a corporate update highlighting positive preclinical results for lead candidate EB-003 and intellectual property developments. The company is preparing an IND submission for EB-003 and raised $12.2 million in gross proceeds during fiscal year 2025.
Key takeaways
Reported net loss of $4.0 million for Q4 2025 with basic and diluted loss per share of $6.12
Had cash-on-hand of $4.7 million as of December 31, 2025
Raised gross proceeds of $12.2 million during fiscal year 2025 through offerings
Received FDA response allowing for streamlined plans for EB-003 IND submission
Completed reverse stock split on October 28, 2025 at ratio of 1 post-split share for every 12 pre-split shares
Withdrawal of Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against Enveric's U.S. Patent No. 12,138,276